Northern Trust’s Artelo Biosciences ARTL Stock Holding History

Northern Trust’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-26	Closed	-$20K	–	4715
2022 Q2	$20K	Hold	26	–	–	﹤0.01%	4622
2022 Q1	$28K	Hold	26	–	–	﹤0.01%	4633
2021 Q4	$32K	Hold	26	–	–	﹤0.01%	4657
2021 Q3	$49K	Buy	26 +21	+420%	+$48K	﹤0.01%	4538
2021 Q2	$15K	Hold	5	–	–	﹤0.01%	4549
2021 Q1	$20K	Hold	5	–	–	﹤0.01%	4436
2020 Q4	$9K	Buy	+5	New	+$7.74K	﹤0.01%	4347

Other funds holding ARTL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Northern Trust's ARTL Position: Q3 2022 in Review

Northern Trust sold out of Artelo Biosciences (ARTL) in Q3 2022, closing a stake of 26 shares — an estimated $20K sold.

Northern Trust first reported a position in ARTL in Q4 2020 and held it in 7 quarters. The position peaked at $49K in Q3 2021. 6 funds tracked by Wall St. Rank hold ARTL as of Q3 2022.

Northern Trust reported no remaining Artelo Biosciences position as of Q3 2022 after selling out during the quarter.
Northern Trust sold 26 Artelo Biosciences shares in Q3 2022, an estimated $20K.
Northern Trust first reported a position in Artelo Biosciences in Q4 2020 and held it in 7 quarters.
Northern Trust's Artelo Biosciences position peaked at $49K in Q3 2021.
6 funds tracked by Wall St. Rank held Artelo Biosciences as of Q3 2022.

Based on Northern Trust's 13F filing for Q3 2022, filed 14 Nov 2022.